BUB1

Across TCGA pan-cancer cohorts, BUB1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated BUB1 data layer compared with 30 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher BUB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BUB1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LIHC, LUSC, and BLCA are the cancer types where BUB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.125	0.786	<.001	24	view →
LUSC	OS	Median	II,III,IV	0.126	0.732	<.001	18	view →
BLCA	OS	Median	II,III,IV	0.926	0.595	.014	12	view →
COAD	DFS	Median	All	0.162	0.569	.021	11	view →
UCEC	DFS	Median	All	0.970	0.828	.017	10	view →
SKCM	DFS	Median	III,IV	0.075	0.655	<.001	9	view →
BRCA	OS	Median	All	0.112	0.578	.031	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	DFS	Median	II,III,IV	0.192	0.752	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

BUB1–LIHC (OS)

Open the LIHC breakdown →